Loading...
Please wait, while we are loading the content...
Similar Documents
Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Gonçales, Fernando Lopes Vigani, Aline Gonzalez Gonçales, Neiva Sellan Lopes Barone, Antônio Alci Araújo, Evaldo Stanislau Affonso De Focaccia, Roberto Oliveira, Umbeliana Barbosa De Coelho, Henrique Sérgio Morais Paixão, Jacqueline Bittencourt Althoff Perez, Renata De Mello Lobato, Cirley Weirich, Judith Rosa, Heitor Borges, Andrelina Vila, Ricardo Corrêa-Giannella, Maria Lúcia Cardillo Ferraz, Maria L. |
| Copyright Year | 2006 |
| Abstract | Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (<65 kg, 65-85 kg and >85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression. |
| Starting Page | 1 |
| Ending Page | 5 |
| Page Count | 5 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.scielo.br/pdf/bjid/v10n5/a02v10n5.pdf |
| PubMed reference number | 17293917v1 |
| Volume Number | 10 |
| Issue Number | 5 |
| Journal | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Chemical and Drug Induced Liver Injury Combined Modality Therapy Congenital Abnormality Depressive disorder Genotyping Techniques Hematological Disease Hepatitis, Chronic Patients Ribavirin Sixty Nine Total Peripheral Resistance peginterferon alfa-2b |
| Content Type | Text |
| Resource Type | Article |
